Humoral Immune Pressure Selects for HIV-1 CXC-chemokine Receptor 4-using Variants
Gonzalez, Oscar A.
Sagar, ManishNote: Order does not necessarily reflect citation order of authors.
MetadataShow full item record
CitationLin, N., O. A. Gonzalez, L. Registre, C. Becerril, B. Etemad, H. Lu, X. Wu, et al. 2016. “Humoral Immune Pressure Selects for HIV-1 CXC-chemokine Receptor 4-using Variants.” EBioMedicine 8 (1): 237-247. doi:10.1016/j.ebiom.2016.04.040. http://dx.doi.org/10.1016/j.ebiom.2016.04.040.
AbstractAlthough both C-C chemokine receptor 5 (CCR5)- and CXC chemokine receptor 4 (CXCR4)-using HIV-1 strains cause AIDS, the emergence of CXCR4-utilizing variants is associated with an accelerated decline in CD4 + T cells. It remains uncertain if CXCR4-using viruses hasten disease or if these variants only emerge after profound immunological damage. We show that exclusively CXCR4- as compared to cocirculating CCR5-utilizing variants are less sensitive to neutralization by both contemporaneous autologous plasma and plasma pools from individuals that harbor only CCR5-using HIV-1. The CXCR4-utilizing variants, however, do not have a global antigenic change because they remain equivalently susceptible to antibodies that do not target coreceptor binding domains. Studies with envelope V3 loop directed antibodies and chimeric envelopes suggest that the neutralization susceptibility differences are potentially influenced by the V3 loop. In vitro passage of a neutralization sensitive CCR5-using virus in the presence of autologous plasma and activated CD4 + T cells led to the emergence of a CXCR4-utilizing virus in 1 of 3 cases. These results suggest that in some but not necessarily all HIV-1 infected individuals humoral immune pressure against the autologous virus selects for CXCR4-using variants, which potentially accelerates disease progression. Our observations have implications for using antibodies for HIV-1 immune therapy.
Citable link to this pagehttp://nrs.harvard.edu/urn-3:HUL.InstRepos:27662291